entertainment -WSS

entertainment

author：hotspot 2025-09-29 23:12:17 - browse：1

A phone screen displays the webpage of Medicare.gov — coverage from STAT — Adobe

Over the past few weeks, Medicare Advantage insurers demanded that the Biden administration give them higher payment rates for next year. The government’s data on how much people were using health care didn’t match their own data, insurers and lobbyists griped — and therefore they wouldn’t be paid enough to cover those costs.

But the federal government was not persuaded by the industry’s data or lobbying push. The Biden administration and its Medicare agency decided to stick with their proposals from January on Monday, dealing a blow to an insurance industry that has come to rely on Medicare Advantage for a steady stream of profits.

The result: In 2025, right after a new president is elected, Medicare Advantage insurers will have to absorb a slight decrease of 0.2% to the baseline payment rates that insurers receive from the government for enrolling older adults and people with disabilities. The stock prices of the largest Medicare Advantage insurers — UnitedHealth, Humana, CVS Health, and Elevance Health — all fell by at least 4% in after-hours trading.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： FDA gives detailed accounting of AI

entertainment

leisure time

WSS

Alabama hospital puts IVF treatments on hold

New documents shed light on MD Anderson Cancer Institute feud

NIH study of ME/CFS points to clear biological hallmarks

R1 RCM gets $5.8 billion buyout offer from private equity firm

How climate

STAT Summit: How a Chicago ER doctor tackles gun violence

focus

entertainment

hotspot

Cancer drug shortages should be causing more outrage

First Opinion Podcast: Long Covid needs a new approach

Medical records are filled with copy

Ed Silverman on new gene therapies, biosimilars, coffee, and more

Novavax promises a turnaround & Lilly roils the obesity market

Pharmacists can make shortage drugs, but at what cost?

After affirmative action ruling, medical educators look to 'holistic review'

Will Ozempic

Duchenne breakthrough therapy leaves behind pioneering families

6 phony surgeries that take placebo to the extreme

hotspot

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

Solve the antibiotic resistance crisis with preventive drugs

STAT Summit: GSK CEO on pharma giant's new direction

STAT Summit: Michael J. Fox on progress in Parkinson's research

FDA gives detailed accounting of AI

HHS leader on health, climate change and biopharma emissions

entertainment

leisure time

knowledge

focus